Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: A randomized clinical trial

JAMA Ophthalmology

Volumn 135, Issue 11, 2017, Pages 1206-1213

  Koh, Adrian ^a   Lai, Timothy Y Y ^b   Takahashi, Kanji ^c   Wong, Tien Y ^d   Chen, Lee Jen ^e   Ruamviboonsuk, Paisan ^f   Tan, Colin S ^g,h   Feller, Chrystel ⁱ   Margaron, Philippe ⁱ   Lim, Tock H ^g,h   Lee, Won Ki ^j  

^a Camden Medical Centre   (Singapore)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f RAJAVITHI HOSPITAL   (Thailand)

^g NATIONAL HEALTHCARE GROUP EYE INSTITUTE   (Singapore)

^h TAN TOCK SENG HOSPITAL   (Singapore)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j The Catholic University of Korea   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; PHOTOSENSITIZING AGENT; PORPHYRIN;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; COMPARATIVE EFFECTIVENESS; CONJUNCTIVITIS; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; INJECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; THICKNESS; TREATMENT DURATION; VERY ELDERLY; VITREOUS HEMORRHAGE; CHOROID; CHOROID DISEASE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PHASE 4 CLINICAL TRIAL; PHOTOCHEMOTHERAPY; POLYP; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VASCULARIZATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROID; CHOROID DISEASES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INJECTIONS, INTRAVENOUS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; POLYPS; PORPHYRINS; RANIBIZUMAB; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85034637868     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2017.4030     Document Type: Article

References (32)

1. Wong RL, Lai TY. Polypoidal choroidal vasculopathy: an update on therapeutic approaches. J Ophthalmic Vis Res. 2013;8(4):359-371.
2. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1-8.
3. Cheung CM, Laude A, Wong W, et al. Improved specificity of polypoidal choroidal vasculopathy diagnosis using a modified EVEREST criteria. Retina. 2015;35(7):1375-1380.
4. Kokame GT. Polypoidal choroidal vasculopathy: an important diagnosis to make with therapeutic implications. Retina. 2012;32(8):1446-1448.
5. Khan S, Engelbert M, Imamura Y, Freund KB. Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings. Retina. 2012;32(6):1057-1068.
6. Rosa RH Jr, Davis JL, Eifrig CW. Clinicopathologic reports, case reports, and small case series: clinicopathologic correlation of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 2002;120(4):502-508.
7. Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res. 2010;29(1): 19-29.
8. Cackett P, Yeo I, Cheung CM, et al. Relationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age-related macular degeneration in Chinese persons. Ophthalmology. 2011;118(5):846-852.
9. Cheung CM, Laude A, Yeo I, et al. Systemic, ocular, and genetic risk factors for age-related macular degeneration and polypoidal choroidal vasculopathy in singaporeans. Sci Rep. 2017;7(7): 41386.
10. Koh AH, Chen LJ, Chen SJ, et al; Expert PCV Panel. Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. 2013;33(4):686-716.
11. Wong CW, Yanagi Y, Lee WK, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53: 107-139.
12. Tan CS, Ngo WK, Chen JP, Tan NW, Lim TH; EVEREST Study Group. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99(5):624-628.
13. Lim TH, Laude A, Tan CS. Polypoidal choroidal vasculopathy: an angiographic discussion. Eye (Lond). 2010;24(3):483-490.
14. Honda S, Matsumiya W, Negi A. Polypoidal choroidal vasculopathy: clinical features and genetic predisposition. Ophthalmologica. 2014;231 (2):59-74.
15. Iida T. Polypoidal choroidal vasculopathy with an appearance similar to classic choroidal neovascularisation on fluorescein angiography. Br J Ophthalmol. 2007;91(9):1103-1104.
16. Tang K, Si JK, Guo DD, et al. Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis. Int J Ophthalmol. 2015;8(5): 1056-1066.
17. Cheung CM, Lai TY, Chen SJ, et al. Understanding indocyanine green angiography in polypoidal choroidal vasculopathy: the group experience with digital fundus photography and confocal scanning laser ophthalmoscopy. Retina. 2014;34(12):2397-2406.
18. Tan CS, Ngo WK, Lim LW, Tan NW, Lim TH; EVEREST Study Group. EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy: lessons learnt from screening failures in the EVEREST study. Graefes Arch Clin Exp Ophthalmol. 2016;254(10):1923-1930.
19. Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453-1464.
20. Oishi A, Kojima H, Mandai M, et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol. 2013;156 (4):644-651.
21. Gomi F, Oshima Y, Mori R, et al; Fujisan Study Group. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan Study. Retina. 2015;35(8):1569-1576.
22. Li X, Zhu A, Egger A, et al. Ranibizumab 0.5 mg in patients with polypoidal choroidal vasculopathy: results from the DRAGON study. Paper presented at: American Academy of Ophthalmology; October 17, 2016; Chicago, IL.
23. Iida T. Results of the Planet Study. Paper presented at: Asia-Pacific Vitreo-retina Society Annual Meeting; December 9, 2016; Bangkok, Thailand.
24. Wang W, He M, Zhang X. Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies. PLoS One. 2014;9(10):e110667.
25. Sakai T, Okano K, Kohno H, Tsuneoka H. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy. Acta Ophthalmol. 2016;94(8):e765-e771.
26. Akaza E, Yuzawa M, Matsumoto Y, Kashiwakura S, Fujita K, Mori R. Role of photodynamic therapy in polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2007;51(4):270-277.
27. Saito M, Nagayama D, Iida T. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy: long-term results. Nippon Ganka Gakkai Zasshi. 2009;113(8):792-799.
28. Lee WK, Lee PY, Lee SK. Photodynamic therapy for polypoidal choroidal vasculopathy: vaso-occlusive effect on the branching vascular network and origin of recurrence. Jpn J Ophthalmol. 2008;52(2):108-115.
29. Lee YH, Lee EK, Shin KS, Lee KM, Kim JY. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy. Retina. 2011;31(7):1287-1293.
30. Hirami Y, Tsujikawa A, Otani A, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina. 2007;27(3):335-341.
31. Byeon SH, Lew YJ, Lee SC, Kwon OW. Clinical features and follow-up results of pulsating polypoidal choroidal vasculopathy treated with photodynamic therapy. Acta Ophthalmol. 2010;88 (6):660-668.
32. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy. Korean J Ophthalmol. 2010;24(3):155-158.